Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study.
Journal
Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
10
09
2023
accepted:
19
04
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
4
6
2024
Statut:
aheadofprint
Résumé
In contrast to the many reports of successful real-world cases of personalized bacteriophage therapy (BT), randomized controlled trials of non-personalized bacteriophage products have not produced the expected results. Here we present the outcomes of a retrospective observational analysis of the first 100 consecutive cases of personalized BT of difficult-to-treat infections facilitated by a Belgian consortium in 35 hospitals, 29 cities and 12 countries during the period from 1 January 2008 to 30 April 2022. We assessed how often personalized BT produced a positive clinical outcome (general efficacy) and performed a regression analysis to identify functional relationships. The most common indications were lower respiratory tract, skin and soft tissue, and bone infections, and involved combinations of 26 bacteriophages and 6 defined bacteriophage cocktails, individually selected and sometimes pre-adapted to target the causative bacterial pathogens. Clinical improvement and eradication of the targeted bacteria were reported for 77.2% and 61.3% of infections, respectively. In our dataset of 100 cases, eradication was 70% less probable when no concomitant antibiotics were used (odds ratio = 0.3; 95% confidence interval = 0.127-0.749). In vivo selection of bacteriophage resistance and in vitro bacteriophage-antibiotic synergy were documented in 43.8% (7/16 patients) and 90% (9/10) of evaluated patients, respectively. We observed a combination of antibiotic re-sensitization and reduced virulence in bacteriophage-resistant bacterial isolates that emerged during BT. Bacteriophage immune neutralization was observed in 38.5% (5/13) of screened patients. Fifteen adverse events were reported, including seven non-serious adverse drug reactions suspected to be linked to BT. While our analysis is limited by the uncontrolled nature of these data, it indicates that BT can be effective in combination with antibiotics and can inform the design of future controlled clinical trials. BT100 study, ClinicalTrials.gov registration: NCT05498363 .
Identifiants
pubmed: 38834776
doi: 10.1038/s41564-024-01705-x
pii: 10.1038/s41564-024-01705-x
doi:
Banques de données
ClinicalTrials.gov
['NCT05498363']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Kim Win Pang
(KW)
Willem-Jan Metsemakers
(WJ)
Dimitri Van der Linden
(D)
Olga Chatzis
(O)
Anaïs Eskenazi
(A)
Angel Lopez
(A)
Adrien De Voeght
(A)
Anne Françoise Rousseau
(AF)
Anne Tilmanne
(A)
Daphne Vens
(D)
Jean Gérain
(J)
Brice Layeux
(B)
Erika Vlieghe
(E)
Ingrid Baar
(I)
Sabrina Van Ierssel
(S)
Johan Van Laethem
(J)
Julien Guiot
(J)
Sophie De Roock
(S)
Serge Jennes
(S)
Saartje Uyttebroek
(S)
Laura Van Gerven
(L)
Peter W Hellings
(PW)
Lieven Dupont
(L)
Yves Debaveye
(Y)
David Devolder
(D)
Isabel Spriet
(I)
Paul De Munter
(P)
Melissa Depypere
(M)
Michiel Vanfleteren
(M)
Olivier Cornu
(O)
Stijn Verhulst
(S)
Tine Boiy
(T)
Stoffel Lamote
(S)
Thibaut Van Zele
(T)
Grégoire Wieërs
(G)
Cécile Courtin
(C)
David Lebeaux
(D)
Jacques Sartre
(J)
Tristan Ferry
(T)
Frédéric Laurent
(F)
Kevin Paul
(K)
Mariagrazia Di Luca
(M)
Stefan Gottschlich
(S)
Tamta Tkhilaishvili
(T)
Novella Cesta
(N)
Karlis Racenis
(K)
Telma Barbosa
(T)
Luis Eduardo López-Cortés
(LE)
Maria Tomás
(M)
Martin Hübner
(M)
Truong-Thanh Pham
(TT)
Paul Nagtegaal
(P)
Jaap Ten Oever
(J)
Johannes Daniels
(J)
Maartje Loubert
(M)
Ghariani Iheb
(G)
Joshua Jones
(J)
Lesley Hall
(L)
Matthew Young
(M)
Nana Balarjishvili
(N)
Marina Tediashvili
(M)
Yigang Tong
(Y)
Christine Rohde
(C)
Johannes Wittmann
(J)
Ronen Hazan
(R)
Ran Nir-Paz
(R)
Joana Azeredo
(J)
Victor Krylov
(V)
David Cameron
(D)
Melissa Pitton
(M)
Yok-Ai Que
(YA)
Gregory Resch
(G)
Shawna McCallin
(S)
Matthew Dunne
(M)
Samuel Kilcher
(S)
Informations de copyright
© 2024. The Author(s).
Références
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).
doi: 10.1016/S0140-6736(21)02724-0
Dublanchet, A. & Fruciano, E. Brève histoire de la phagothérapie [A short history of phage therapy]. Med. Mal. Infect. 38, 415–420 (2008).
pubmed: 18692974
doi: 10.1016/j.medmal.2008.06.016
Uyttebroek, S. et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect. Dis. 22, e208–e220 (2022).
pubmed: 35248167
doi: 10.1016/S1473-3099(21)00612-5
Pirnay, J.-P. & Kutter, E. Bacteriophages: it’s a medicine, Jim, but not as we know it. Lancet Infect. Dis. 21, 309–311 (2021).
pubmed: 32949499
doi: 10.1016/S1473-3099(20)30464-3
Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, e00954-17 (2017).
pubmed: 28807909
pmcid: 5610518
doi: 10.1128/AAC.00954-17
Eskenazi, A. et al. Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae. Nat. Commun. 13, 302 (2022).
pubmed: 35042848
pmcid: 8766457
doi: 10.1038/s41467-021-27656-z
Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730–733 (2019).
pubmed: 31068712
pmcid: 6557439
doi: 10.1038/s41591-019-0437-z
Pirnay, J. P. et al. The magistral phage. Viruses 10, 64 (2018).
pubmed: 29415431
pmcid: 5850371
doi: 10.3390/v10020064
Instructions for the Administration of Liquid Staphylococcal Bacteriophage Preparations for Injection (in Russian) (Ministry of Health and Ministry of Medical and Microbiological Industry of the USSR, 1987).
Instructions for the Application of Liquid Streptococcal Bacteriophage Preparations (in Russian) (Ministry of Health and Ministry of Medical and Microbiology Industry of the USSR, 1987).
Instructions for the Application of Combined Liquid Pyobacteriophage Preparations (in Russian) (Ministry of Medical and Microbiology Industry of the USSR, 1989).
Djebara, S. et al. Processing phage therapy requests in a Brussels military hospital: lessons identified. Viruses 11, 265 (2019).
pubmed: 30884879
pmcid: 6466067
doi: 10.3390/v11030265
Young, M. J. et al. Phage therapy for diabetic foot infection: a case series. Clin. Ther. 45, 797–801 (2023).
pubmed: 37442654
doi: 10.1016/j.clinthera.2023.06.009
Vogt, D. et al. “Beyond antibiotic therapy” – Zukünftige antiinfektiöse Strategien – Update 2017 [Beyond antibiotic therapy – Future antiinfective strategies – Update 2017]. Unfallchirurg 120, 573–584 (2017).
pubmed: 28643099
doi: 10.1007/s00113-017-0374-6
Jennes, S. et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—a case report. Crit. Care 21, 129 (2017).
pubmed: 28583189
pmcid: 5460490
doi: 10.1186/s13054-017-1709-y
Lebeaux, D. et al. A case of phage therapy against pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient. Viruses 13, 60 (2021).
pubmed: 33466377
pmcid: 7824836
doi: 10.3390/v13010060
Van Nieuwenhuyse, B. et al. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nat. Commun. 13, 5725 (2022).
pubmed: 36175406
pmcid: 9523064
doi: 10.1038/s41467-022-33294-w
Van Nieuwenhuyse, B. et al. A case of in situ phage therapy against Staphylococcus aureus in a bone allograft polymicrobial biofilm infection: outcomes and phage-antibiotic interactions. Viruses 13, 1898 (2021).
pubmed: 34696328
pmcid: 8539586
doi: 10.3390/v13101898
Onsea, J. et al. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. Viruses 11, 891 (2019).
pubmed: 31548497
pmcid: 6832313
doi: 10.3390/v11100891
Ferry, T. et al. Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nat. Commun. 13, 4239 (2022).
pubmed: 35869081
pmcid: 9306240
doi: 10.1038/s41467-022-31837-9
Racenis, K. et al. Use of phage cocktail BFC 1.10 in combination with ceftazidime-avibactam in the treatment of multidrug-resistant Pseudomonas aeruginosa femur osteomyelitis - a case report. Front. Med. 9, 851310 (2022).
doi: 10.3389/fmed.2022.851310
Bakuradze, N. et al. Characterization of a bacteriophage GEC_vB_Bfr_UZM3 active against Bacteroides fragilis. Viruses 15, 1042 (2023).
pubmed: 37243129
pmcid: 10222676
doi: 10.3390/v15051042
Paul, K. et al. Bacteriophage rescue therapy of a vancomycin-resistant Enterococcus faecium infection in a one-year-old child following a third liver transplantation. Viruses 13, 1785 (2021).
pubmed: 34578366
pmcid: 8472888
doi: 10.3390/v13091785
Tkhilaishvili, T. et al. Successful case of adjunctive intravenous bacteriophage therapy to treat left ventricular assist device infection. J. Infect. 83, e1–e3 (2021).
pubmed: 34058260
doi: 10.1016/j.jinf.2021.05.027
Racenis, K. et al. Successful bacteriophage–antibiotic combination therapy against multidrug-resistant Pseudomonas aeruginosa left ventricular assist device driveline infection. Viruses 15, 1210 (2023).
pubmed: 37243293
pmcid: 10223274
doi: 10.3390/v15051210
Blasco, L. et al. Case report: analysis of phage therapy failure in a patient with a Pseudomonas aeruginosa prosthetic vascular graft infection. Front. Med. 10, 1199657 (2023).
doi: 10.3389/fmed.2023.1199657
Takeuchi, I. et al. The presence of two receptor-binding proteins contributes to the wide host range of staphylococcal twort-like phages. Appl. Environ. Microbiol. 82, 5763–5774 (2016).
pubmed: 27422842
pmcid: 5038044
doi: 10.1128/AEM.01385-16
Treepong, P. et al. Global emergence of the widespread Pseudomonas aeruginosa ST235 clone. Clin. Microbiol. Infect. 24, 258–266 (2018).
pubmed: 28648860
doi: 10.1016/j.cmi.2017.06.018
Hrabák, J. et al. Regional spread of Pseudomonas aeruginosa ST357 producing IMP-7 metallo-β-lactamase in Central Europe. J. Clin. Microbiol. 49, 474–475 (2011).
pubmed: 20980582
doi: 10.1128/JCM.00684-10
Ceyssens, P. J. et al. Phenotypic and genotypic variations within a single bacteriophage species. Virol. J. 8, 134 (2011).
pubmed: 21429206
pmcid: 3072928
doi: 10.1186/1743-422X-8-134
Kilmury, S. L. N. & Burrows, L. L. The Pseudomonas aeruginosa PilSR two-component system regulates both twitching and swimming motilities. mBio 9, e01310–e01318 (2018).
pubmed: 30042200
pmcid: 6058289
doi: 10.1128/mBio.01310-18
Nunn, D., Bergman, S. & Lory, S. Products of three accessory genes, pilB, pilC, and pilD, are required for biogenesis of Pseudomonas aeruginosa pili. J. Bacteriol. 172, 2911–2919 (1990).
pubmed: 1971619
pmcid: 209088
doi: 10.1128/jb.172.6.2911-2919.1990
Wehbi, H. et al. The peptidoglycan-binding protein FimV promotes assembly of the Pseudomonas aeruginosa type IV pilus secretin. J. Bacteriol. 193, 540–550 (2011).
pubmed: 21097635
doi: 10.1128/JB.01048-10
Kropinski, A. M., Chan, L., Jarrell, K. & Milazzo, F. H. The nature of Pseudomonas aeruginosa strain PAO bacteriophage receptors. Can. J. Microbiol. 23, 653–658 (1977).
pubmed: 406024
doi: 10.1139/m77-098
Koderi Valappil, S. et al. Survival comes at a cost: a coevolution of phage and its host leads to phage resistance and antibiotic sensitivity of Pseudomonas aeruginosa multidrug resistant strains. Front. Microbiol. 12, 783722 (2021).
pubmed: 34925289
pmcid: 8678094
doi: 10.3389/fmicb.2021.783722
Yoshida, H., Bogaki, M., Nakamura, M. & Nakamura, S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34, 1271–1272 (1990).
pubmed: 2168148
pmcid: 171799
doi: 10.1128/AAC.34.6.1271
Takenouchi, T., Sakagawa, E. & Sugawara, M. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrob. Agents Chemother. 43, 406–409 (1999).
pubmed: 9925546
pmcid: 89091
doi: 10.1128/AAC.43.2.406
Yonezawa, M. et al. Analysis of the NH
pubmed: 8569537
doi: 10.1111/j.1348-0421.1995.tb02236.x
Nakajima, A., Sugimoto, Y., Yoneyama, H. & Nakae, T. High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation. Microbiol. Immunol. 46, 391–395 (2002).
pubmed: 12153116
doi: 10.1111/j.1348-0421.2002.tb02711.x
Church, D., Elsayed, S., Reid, O., Winston, B. & Lindsay, R. Burn wound infections. Clin. Microbiol. Rev. 19, 403–434 (2006).
pubmed: 16614255
pmcid: 1471990
doi: 10.1128/CMR.19.2.403-434.2006
Rose, T. et al. Experimental phage therapy of burn wound infection: difficult first steps. Int. J. Burns Trauma 4, 66–73 (2014).
pubmed: 25356373
pmcid: 4212884
Pirnay, J.-P. Phage therapy in the year 2035. Front. Microbiol. 11, 1171 (2020).
pubmed: 32582107
pmcid: 7284012
doi: 10.3389/fmicb.2020.01171
Suh, G. A. et al. Considerations for the use of phage therapy in clinical practice. Antimicrob. Agents Chemother. 66, e0207121 (2022).
pubmed: 35041506
doi: 10.1128/aac.02071-21
Luria, S. E. & Delbrück, M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28, 491–511 (1943).
pubmed: 17247100
pmcid: 1209226
doi: 10.1093/genetics/28.6.491
Castledine, M. et al. Parallel evolution of Pseudomonas aeruginosa phage resistance and virulence loss in response to phage treatment in vivo and in vitro. Elife 11, e73679 (2022).
pubmed: 35188102
pmcid: 8912922
doi: 10.7554/eLife.73679
Westra, E. R. et al. Parasite exposure drives selective evolution of constitutive versus inducible defense. Curr. Biol. 25, 1043–1049 (2015).
pubmed: 25772450
doi: 10.1016/j.cub.2015.01.065
Gu Liu, C. et al. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. mBio 11, e01462–20 (2020).
pubmed: 32753497
pmcid: 7407087
doi: 10.1128/mBio.01462-20
Fungo, G. B. N. et al. “Two Is Better Than One”: the multifactorial nature of phage-antibiotic combinatorial treatments against ESKAPE-induced infections. Phage 4, 55–67 (2023).
pubmed: 37350995
doi: 10.1089/phage.2023.0007
Torres-Barceló, C. & Hochberg, M. E. Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. 24, 249–256 (2016).
pubmed: 26786863
doi: 10.1016/j.tim.2015.12.011
Torres-Barceló, C. Phage therapy faces evolutionary challenges. Viruses 10, 323 (2018).
pubmed: 29895791
pmcid: 6024868
doi: 10.3390/v10060323
Chan, B. K. et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6, 26717 (2016).
pubmed: 27225966
pmcid: 4880932
doi: 10.1038/srep26717
Abedon, S. T. Phage-antibiotic combination treatments: antagonistic impacts of antibiotics on the pharmacodynamics of phage therapy? Antibiotics 8, 182 (2019).
pubmed: 31614449
pmcid: 6963693
doi: 10.3390/antibiotics8040182
Górski, A. et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41–71 (2012).
pubmed: 22748808
doi: 10.1016/B978-0-12-394438-2.00002-5
Instructions for the Application of a Liquid Staphylococcal Phage Preparation for Injection (in Russian) (Ministry of Health of the USSR, 1986).
Dedrick, R. M. et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat. Med. 27, 1357–1361 (2021).
pubmed: 34239133
pmcid: 8571776
doi: 10.1038/s41591-021-01403-9
Onsea, J. et al. Bacteriophage therapy for difficult-to-treat infections: the implementation of a multidisciplinary phage task force (The PHAGEFORCE Study Protocol). Viruses 13, 1543 (2021).
pubmed: 34452408
pmcid: 8402896
doi: 10.3390/v13081543
Regulation (EU) No 536/2014 OF THE European Parliament and of the Council of 16 April 2014 on Clinical Trials On Medicinal Products For Human Use, And Repealing Directive 2001/20/EC (Official Journal of the European Union, 2014).
Merabishvili, M. et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4, e4944 (2009).
pubmed: 19300511
pmcid: 2654153
doi: 10.1371/journal.pone.0004944
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
pubmed: 24695404
pmcid: 4103590
doi: 10.1093/bioinformatics/btu170
Wick, R. R., Judd, L. M., Gorrie, C. L. & Holt, K. E. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput. Biol. 13, e1005595 (2017).
pubmed: 28594827
pmcid: 5481147
doi: 10.1371/journal.pcbi.1005595
Prjibelski, A., Antipov, D., Meleshko, D., Lapidus, A. & Korobeynikov, A. Using SPAdes de novo assembler. Curr. Protoc. Bioinformatics 70, e102 (2020).
pubmed: 32559359
doi: 10.1002/cpbi.102
Seemann, T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30, 2068–2069 (2014).
pubmed: 24642063
doi: 10.1093/bioinformatics/btu153
Arndt, D. et al. PHASTER: a better, faster version of the PHAST phage search tool. Nucleic Acids Res. 44, W16–W21 (2016).
pubmed: 27141966
pmcid: 4987931
doi: 10.1093/nar/gkw387
Song, W. et al. Prophage Hunter: an integrative hunting tool for active prophages. Nucleic Acids Res. 47, W74–W80 (2019).
pubmed: 31114893
pmcid: 6602508
doi: 10.1093/nar/gkz380
Kutter, E. Phage host range and efficiency of plating. Methods Mol. Biol. 501, 141–149 (2009).
pubmed: 19066818
doi: 10.1007/978-1-60327-164-6_14
Friman, V. P. et al. Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. J. Evol. Biol. 29, 188–198 (2016).
pubmed: 26476097
doi: 10.1111/jeb.12774
Appelmans, R. Le dosage du Bacteriophage. (in French) Compt. Rend. Soc. Biol. 85, 1098 (1921).
Burrowes, B. H., Molineux, I. J. & Fralick, J. A. Directed in vitro evolution of therapeutic bacteriophages: the Appelmans Protocol. Viruses 11, 241 (2019).
pubmed: 30862096
pmcid: 6466182
doi: 10.3390/v11030241
Department for Industrial Bacterial and Viral Preparations. Guidelines for the Production of Combined Pyobacteriophage Solutions. N242-82 (in Russian) (Ministry of Health of the USSR, 1982).
Guidelines for the Production of Staphylococcal Bacteriophage Solutions for Injection (in Russian) (Ministry of Health of the USSR, 1986).
Department for the Monitoring of the Introduction of New Medicines and Medical Equipment. Staphylococcal Bacteriophage Solutions for Injection. BФC 42-68BC-87 (in Russian) (Ministry of Health of the USSR, Pharmacopoeia Commission, 1987).
Pharmacopoeia Article Concerning Combined Pyobacteriophage Solutions. ФC 42-240BC-8 (in Russian) (Ministry of Health of the USSR, Pharmacopoeia Commission, 1989).
Merabishvili, M., Pirnay, J.-P. & De Vos, D. Guidelines to compose an ideal bacteriophage cocktail. Methods Mol. Biol. 1693, 99–110 (2018).
pubmed: 29119435
doi: 10.1007/978-1-4939-7395-8_9
Duyvejonck, H. et al. Evaluation of the stability of bacteriophages in different solutions suitable for the production of magistral preparations in Belgium. Viruses 13, 865 (2021).
pubmed: 34066841
pmcid: 8151234
doi: 10.3390/v13050865
Merabishvili, M. et al. Stability of bacteriophages in burn wound care products. PLoS ONE 12, e0182121 (2017).
pubmed: 28750102
pmcid: 5531522
doi: 10.1371/journal.pone.0182121
Astudillo, A., Leung, S. S. Y., Kutter, E., Morales, S. & Chan, H. K. Nebulization effects on structural stability of bacteriophage PEV 44. Eur. J. Pharm. Biopharm. 125, 124–130 (2018).
pubmed: 29353018
doi: 10.1016/j.ejpb.2018.01.010
Carrigy, N. B. et al. Anti-tuberculosis bacteriophage D29 delivery with a vibrating mesh nebulizer, jet nebulizer, and soft mist inhaler. Pharm. Res. 34, 2084–2096 (2017).
pubmed: 28646325
doi: 10.1007/s11095-017-2213-4
Aslam, S. et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect. Dis. 7, ofaa389 (2020).
pubmed: 33005701
pmcid: 7519779
doi: 10.1093/ofid/ofaa389
Cano, E. J. et al. Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniae infection: case report and in vitro characterization of anti-biofilm activity. Clin. Infect. Dis. 73, e144–e151 (2021).
pubmed: 32699879
doi: 10.1093/cid/ciaa705
Cantalapiedra, C. P., Hernández-Plaza, A., Letunic, I., Bork, P. & Huerta-Cepas, J. eggNOG-mapper v2: functional annotation, orthology assignments, and domain prediction at the metagenomic scale. Mol. Biol. Evol. 38, 5825–5829 (2021).
pubmed: 34597405
pmcid: 8662613
doi: 10.1093/molbev/msab293
Brown, C. L. et al. mobileOG-db: a manually curated database of protein families mediating the life cycle of bacterial mobile genetic elements. Appl. Environ. Microbiol. 88, e0099122 (2022).
pubmed: 36036594
doi: 10.1128/aem.00991-22
Starikova, E. V. et al. Phigaro: high-throughput prophage sequence annotation. Bioinformatics 36, 3882–3884 (2020).
pubmed: 32311023
doi: 10.1093/bioinformatics/btaa250
Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res. 19, 1639–1645 (2009).
pubmed: 19541911
pmcid: 2752132
doi: 10.1101/gr.092759.109
Gao, F. & Zhang, C. T. GC-Profile: a web-based tool for visualizing and analyzing the variation of GC content in genomic sequences. Nucleic Acids Res. 34, W686–W691 (2006).
pubmed: 16845098
pmcid: 1538862
doi: 10.1093/nar/gkl040
Page, A. J. et al. Roary: rapid large-scale prokaryote pan genome analysis. Bioinformatics 31, 3691–3693 (2015).
pubmed: 26198102
pmcid: 4817141
doi: 10.1093/bioinformatics/btv421
Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation. Nucleic Acids Res. 49, W293–W296 (2021).
pubmed: 33885785
pmcid: 8265157
doi: 10.1093/nar/gkab301
Adams, M. H. Bacteriophages (Interscience Publishers, 1959).
Harris, P. A. et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).
pubmed: 18929686
doi: 10.1016/j.jbi.2008.08.010
Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268–281 (2012).
pubmed: 21793988
doi: 10.1111/j.1469-0691.2011.03570.x
McDonnell, A. et al. Efficient delivery of investigational antibacterial agents via sustainable clinical trial networks. Clin. Infect. Dis. 63, S57–S59 (2016).
pubmed: 27481955
pmcid: 4967592
doi: 10.1093/cid/ciw244
R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2016).
Wickham, H. et al. Welcome to the tidyverse. J. Open Source Softw. 4, 1686 (2019).
doi: 10.21105/joss.01686
Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 33, 2938–2940 (2017).
pubmed: 28645171
pmcid: 5870712
doi: 10.1093/bioinformatics/btx364
Kahle, D. & Wickham, H. ggmap: spatial visualization with ggplot2. R J. 5, 144–161 (2013).
doi: 10.32614/RJ-2013-014
Massicotte, P. & South, A. rnaturalearth: world map data from natural earth. R package version 0.3.2.9000 https://cran.r-project.org/package=rnaturalearth (2023).